Alkermes (ALKS)
(Delayed Data from NSDQ)
$24.04 USD
-0.33 (-1.35%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $23.94 -0.10 (-0.42%) 7:54 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Product sales, net
- 920.00
- 777.55
- 627.42
- 551.76
- 524.50
- Revenue - Line of Business (LOBR)
- Revenues: Manufacturing and Royalty revenues
- 743.39
- 331.98
- 541.81
- 484.00
- 447.88
- Revenue - Line of Business (LOBR)
- Revenues: Proprietary Sales: VIVITROL
- 400.42
- 379.48
- 343.85
- 310.72
- 335.36
- Revenue - Line of Business (LOBR)
- Revenues: Proprietary Sales: ARISTADA
- 327.69
- 302.05
- 275.36
- 241.04
- 189.14
- Revenue - Line of Business (LOBR)
- Revenues: Proprietary Sales: LYBALVI
- 191.89
- 96.02
- 8.22
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Key Commercial Product Revenues: VUMERITY
- 129.33
- 115.50
- 87.40
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Legacy Product Revenues
- 90.69
- 50.90
- 100.40
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Manufacturing and Royalty Revenues: Long-acting INVEGA products
- 486.10
- 115.70
- 303.10
- 345.60
- 256.95
- Revenue - Line of Business (LOBR)
- Revenues: Manufacturing and Royalty Revenues: RISPERDAL CONSTA
- 37.28
- 49.91
- 87.42
- --
- 66.38